SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.
Recurrent or Metastatic Cervical Cancer
DRUG: SHR-A1811|DRUG: Adebelimab injection|DRUG: Bevacizumab injection|DRUG: SHR-8068|DRUG: Cisplatin injection|DRUG: Carboplatin injection
Grade≥3 drug-related adverse events (TRAEs)., Up to 3 years.|Grade≥3 drug-related serious adverse events (TRAEs)., Up to 3 years.|Objective response rate (ORR)., Up to 3 years.
Duration of response (DOR)., Up to 3 years.|Disease control rate (DCR)., Up to 3 years.|Progression-free survival (PFS)., Up to 3 years.|Overall survival (OS)., Up to 3 years.
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.